• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity &Ageing - Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season

tetano

Editor, Senior Moderator
We have previously reported an age-related impairment in the serum antibody response topandemic (p)2009 H1N1, measured by hemagglutination inhibition assay and ELISA. Thepresent study extends these observations and evaluates IgG subclass distribution in healthyindividuals of different ages vaccinated during the 2011-2012 season.

Results: The 2011-2012 vaccination season was characterized by a vaccine containing the pandemic(p)2009 H1N1 strain for the third consecutive year.

All of our subjects were previouslyimmunized, and therefore seroprotected at t0. Nevertheless, aging impaired the serumantibody response to H1N1, as antibody titers increased after vaccination in young and less inelderly individuals.

The peak of the response was at day 7 (t7), in contrast with what isusually seen at day 21-28, suggesting a memory response characterized by the induction of anIgG subclass with a shorter half-life. We hypothesized that the IgG3 response, with its muchshorter half-life, might be more represented.

Antibodies were predominantly of the IgG1subclass in both age groups, although a robust IgG3 response was also induced and accountedfor a significant proportion of the overall response. IgG2 and IgG4 antibodies were atindiscernible levels.

We showed a much higher percentage of IgG3 (40-50%) than previouslyin the literature (less than 10%). To explain if this was associated with a particular cytokineprofile, we measured H1N1-induced T cell cytokines in vitro and found that IgG3 levels werepositively correlated with TNF-alpha and IL-6.

Moreover, activation-induced cytidine deaminase(AID) mRNA expression, a predictive biomarker of optimal in vivo vaccine response, wasfound to significantly correlate with IgG3 and also with IgG1 similar to what we have shownpreviously for total IgG.

Conclusions: In the 2011-2012 season, the pandemic (p)2009 H1N1 strain was present in the vaccine forthe third consecutive year and therefore each individual was seroprotected at t0. The peak ofthe response was at t7, suggesting a memory response characterized by a robust induction ofIgG3, which was associated with TNF-alpha and IL-6 production.

Both IgG1 and IgG3 responseswere decreased by age. AID was confirmed to be a predictive biomarker of optimal vaccineresponses.

Author: Daniela FrascaAlain DiazMaria RomeroNicholas V MendezAna Marie LandinBonnie B Blomberg
Credits/Source: Immunity &Ageing 2013, 10:14

http://7thspace.com/headlines/43634...ng_the_2011_2012influenza_vaccine_season.html
 
Back
Top Bottom